VNRX - VOLITIONRX LTD
0.5195
-0.001 -0.135%
Share volume: 145,299
Last Updated: 05-07-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$0.52
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2024 | |
| Report Date | 05-10-2023 | 08-14-2023 | 11-14-2023 | 03-25-2024 | 05-13-2024 | 11-14-2024 | |
| Total revenue | 149.808 K | 216.310 K | 165.211 K | 243.973 K | 171.535 K | 474.522 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 149.808 K | 216.310 K | 165.211 K | 243.973 K | 171.535 K | 474.522 K | |
| 44.39% | -23.62% | 47.67% | -29.69% | 176.63% | |||
| Operating expenses | 9.195 M | 9.765 M | 8.818 M | 8.985 M | 8.556 M | 5.290 M | |
| Selling general and admin | 4.289 M | 4.314 M | 4.168 M | 4.441 M | 3.927 M | 1.816 M | |
| Research and development | 4.906 M | 5.451 M | 4.651 M | 4.544 M | 4.630 M | 3.474 M | |
| Total expenses | 9.195 M | 9.765 M | 8.818 M | 8.985 M | 8.556 M | 6.343 M | |
| 6.20% | -9.70% | 1.89% | -4.77% | -25.86% | |||
| Operating income | -9.045 M | -9.549 M | -8.653 M | -8.741 M | -8.385 M | -5.869 M | |
| Ebit | -9.045 M | -9.549 M | -8.653 M | -8.741 M | -8.385 M | -5.780 M | |
| Pretax income | -8.873 M | -9.551 M | -8.453 M | -8.800 M | -8.472 M | -5.869 M | |
| 7.65% | -11.50% | 4.10% | -3.72% | -30.73% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -8.780 M | -9.471 M | -8.370 M | -8.698 M | -8.367 M | 0.000 | |
| -7.88% | 11.62% | -3.92% | 3.80% | 100.00% | |||
| Net income | -8.780 M | -9.471 M | -8.370 M | -8.698 M | -8.367 M | -5.869 M | |
| -7.88% | 11.62% | -3.92% | 3.80% | 29.86% |
